Skip to main content
. 2015 Oct;94(10):1408–1416. doi: 10.1177/0022034515599726

Figure 2.

Figure 2.

Parathyroid hormone (PTH) (1–34) reduces dentin matrix protein 1 (DMP1) levels in mineralized tissue in situ and in cementoblasts in vitro. (A–D) OCCM.30 were treated with 10–7 M PTH or vehicle for 48 h. Compared with the nuclear and cytoplasmic localization of DMP1 C-terminal peptide (green) in controls (A), PTH (1–34) treatment for 48 h decreased DMP1 C-terminal peptide in both the nucleus and cytoplasm (B). The nucleus area was circled by blue lines marked by DAPI staining (not shown). DMP1 C-terminal peptides were downregulated by 18% in the nucleus (C) and by 38% in the cytoplasm (D) of OCCM.30, confirming that PTH (1–34) treatment significantly decreased DMP1 protein expression in both subcellular compartments. (E–H) Immunohistochemistry (IHC) staining of mandible sections from control (n = 3) or PTH (1–34)–treated mice (n = 5) revealed that PTH (1–34) decreased DMP1 localization in matrices of both cellular cementum and alveolar bone (indicated by yellow arrows). Bars indicate 100 µm in panels A and B. DEN, dentin; CC, cellular cementum; PDL, periodontal ligament; AB, alveolar bone. ***P < 0.001, ****P < 0.0001 as calculated by the Student’s t test.